XML 43 R29.htm IDEA: XBRL DOCUMENT v3.19.1
Summary of Significant Accounting Policies - Additional Information (Details)
$ / shares in Units, shares in Millions
 1 Months Ended 12 Months Ended
May 31, 2013
Dec. 31, 2018
USD ($)
Obligation
Customer
Segment
$ / shares
shares
Dec. 31, 2017
USD ($)
Customer
Licensee
Segment
shares
Dec. 31, 2016
USD ($)
Summary Of Significant Accounting Policies [Line Items]        
Cash equivalents investments with original maturities   $ 0 $ 0  
Impairment loss   0 0  
Acquired technology intangible assets   9,400,000    
Useful life (in years) 11 years      
Amortization expense   1,250,000 1,240,000  
2019   1,200,000    
2020   1,200,000    
2021   1,200,000    
2022   1,200,000    
Thereafter   900,000    
Accumulated amortization on intangible assets   $ 5,900,000 4,700,000  
Number of performance obligation | Obligation   1    
Payment terms with customers   The Company’s contracts do not involve financing elements as payment terms with customers are less than one year.    
Revenue recognized   $ 3,671,000 2,689,000  
Qualifying expenditures related to research   2,700,000 3,500,000  
Interest or penalties related to income tax matters   $ 0 $ 0  
Number of operating segment | Segment   1 1  
Dilutive securities excluded from the calculations of diluted loss per share (in shares) | shares   13.7 0.5  
Restricted cash   $ 40,000 $ 675,000 $ 400,000
Cash, cash equivalents   $ 5,261,000 $ 9,550,000 $ 12,600,000
Outstanding Warrants [Member]        
Summary Of Significant Accounting Policies [Line Items]        
Dilutive securities excluded from the calculations of diluted loss per share (in shares) | shares   8.9    
Options and Restricted Stock [Member]        
Summary Of Significant Accounting Policies [Line Items]        
Dilutive securities excluded from the calculations of diluted loss per share (in shares) | shares   0.1    
Preferred Stock and Restricted Stock Awards [Member]        
Summary Of Significant Accounting Policies [Line Items]        
Dilutive securities excluded from the calculations of diluted loss per share (in shares) | shares   4.7    
Customer Concentration Risk [Member] | Product Revenue [Member]        
Summary Of Significant Accounting Policies [Line Items]        
Number of customers | Customer   2 5  
Concentration risk percentage   60.00% 68.00%  
Customer Concentration Risk [Member] | Accounts Receivable [Member]        
Summary Of Significant Accounting Policies [Line Items]        
Number of customers | Customer   2 1  
Concentration risk percentage   70.00% 77.00%  
Number of licensee | Licensee     1  
Royalty [Member]        
Summary Of Significant Accounting Policies [Line Items]        
Revenue recognized   $ 1,000,000    
Development [Member] | BARDA Contract [Member]        
Summary Of Significant Accounting Policies [Line Items]        
Revenue recognized   $ 3,000,000 $ 3,700,000  
2018 Rights Offering [Member]        
Summary Of Significant Accounting Policies [Line Items]        
Redemption price of warrant prior to expiration | $ / shares   $ 0.01    
Common stock price per share for warrant redemption | $ / shares   $ 3.63    
Number of consecutive trading days for warrant redemption   20 days    
Warrants liability fair value   $ 900,000 3,100,000  
Clinical Technology [Member]        
Summary Of Significant Accounting Policies [Line Items]        
Amortization expense   $ 1,200,000 1,200,000  
Minimum [Member]        
Summary Of Significant Accounting Policies [Line Items]        
Useful lives of the assets   3 years    
Maximum [Member]        
Summary Of Significant Accounting Policies [Line Items]        
Useful lives of the assets   5 years    
Letter of Credit [Member]        
Summary Of Significant Accounting Policies [Line Items]        
Letters of credit amount pursuant to lease agreement   $ 40,000 $ 700,000